Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteonecrosis of the jaw--do bisphosphonates pose a risk?

Literature DB >> 17135582

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

John P Bilezikian¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Diphosphonates

Year: 2006 PMID： 17135582 DOI： 10.1056/NEJMp068157

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

68 in total

1. Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw.

Authors: Yoon Ho Kim; Ho Kyung Lee; Seung Il Song; Jeong Keun Lee
Journal: J Korean Assoc Oral Maxillofac Surg Date: 2014-10-24

2. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443

Review 3. Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents.

Authors: E Seeman
Journal: Osteoporos Int Date: 2007-02-17 Impact factor: 4.507

4. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.

Authors: Srinivasan Shanmugarajan; Rimon F Youssef; Parmita Pati; William L Ries; D Sudhaker Rao; Sakamuri V Reddy
Journal: J Cell Biochem Date: 2008-07-01 Impact factor: 4.429

Review 5. Bisphosphonates.

Authors: Ian R Reid
Journal: Skeletal Radiol Date: 2007-08 Impact factor: 2.199

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

1. Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw.

2. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Review 3. Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents.

4. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.

Review 5. Bisphosphonates.

Review 6. Founders lecture 2007: Metabolic bone disease: what has changed in 30 years?

Review 7. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

8. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Review 9. Treatment and prevention of osteoporosis.

Review 10. [Bisphosphonate-associated osteonecrosis of the jaw].